Choroidal Neovascularization Complicating Photodynamic Therapy for Central Serous Retinopathy

Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy

“…However, as there is a high chance for spontaneous resolution of SRF in acute CSC, the safety requirements for a therapy performed in patients in this early disease stage have to be high. Owing to known potential side effects of the PDT treatment, [11][12][13][14][15] PDT is normally not performed in acute CSC. So far those side effects are not described after SML, thus SML might be the better option to treat patients with acute CSC.…”

“…10 However, the PDT also has potential side effects such as RPE atrophy, choroidal neovascularisation, choriocapillaris ischemia, or transient reduction of macular function, even when reduced treatment settings are used. [11][12][13][14][15] Another treatment option is subthreshold micropulse laser (SML) treatment without any visible end point. In contrast to conventional suprathreshold argon laser photocoagulation, the laser energy is delivered in short pulses with enough time in between to allow heat dissipation to prevent thermal structural tissue damage.…”

Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy

“…[1][2][3][15][16][17][18][19][20][21] In a retrospective study, Mudvari et al 29 found that none of the 340 consecutive CSCR patients developed CNV during an approximate 4-year follow-up period (mean of 49 months). However, Spaide et al 30 reported that older patients with CSCR had a lower VA, and were more likely to have diffuse retinal pigment epitheliopathy and secondary CNV than their younger counterparts.…”

“…[16][17][18] Selecting an appropriate fluence rate avoids collateral damage such as atrophy of the RPE, choroidal ischemia, and development of secondary CNV due to less choriocapillaris damage. [19][20][21] This retrospective study targets on a treatment regimen for CNV in chronic CSCR that has not been described in literature before: a combination of IVR/IVB and ICGAguided PDT with half-fluence rate.…”

Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy

“…[9][10][11][12] However, post-PDT complications such as secondary CNV, pigmentary changes of the retinal pigment epithelium (RPE), and persistent choriocapillaris hypoperfusion have been reported. 10,[13][14][15] To minimize these side effects and to obtain the maximum effects, half-dose verteporfin PDT has been conducted successfully in chronic CSC without serious complications. [16][17][18][19] However, the optimal dosage of verteporfin required to treat chronic CSC has not been established.…”